The DRAM2 Knockout K-562 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population targeting the DRAM2 gene in the Homo sapiens K-562 suspension lymphoblastoid cell line. This loss-of-function model provides a genetically defined system for investigating the role of DRAM2 in autophagy, apoptosis, and tumor suppression, enabling researchers to dissect downstream signaling events without the confounding effects of wild-type protein expression. The polyclonal format ensures a heterogeneous knockout population, reflecting the diversity of editing outcomes typically observed in pooled CRISPR screens, and is suitable for functional studies where clonal variation is not desired.
Derived from a 53-year-old female patient with chronic myelogenous leukemia (CML) in blast crisis, the K-562 cell line is a well-established hematopoietic progenitor cell model that carries the BCR-ABL fusion oncogene (Philadelphia chromosome). These cells grow in suspension, exhibit erythroid and granulocytic differentiation potential, and are widely employed in CML research, serving as a standard platform for evaluating tyrosine kinase inhibitor sensitivity, oncogenic signaling, and leukemia cell biology. Their BCR-ABL-positive status renders them particularly relevant for studying the interplay between oncogenic stress and programmed cell death pathways.
DRAM2 (DNA-damage regulated autophagy modulator 2) encodes a lysosomal transmembrane protein that functions downstream of p53 to promote autophagy and apoptosis. Upon DNA damage or oncogenic stress, p53 transcriptionally activates DRAM2, which in turn facilitates autophagic flux by regulating lysosomal acidification and the formation of autolysosomes. DRAM2 interacts with key molecular factors, including DRAM1, BAX, BCL2, and SQSTM1/p62, and its downstream effects involve LC3-II lipidation, LAMP1 redistribution, and activation of caspase-3?Cmediated apoptosis. The pathway is further modulated by upstream regulators such as mTOR and TFEB, positioning DRAM2 at a critical node between lysosomal degradation and cell fate decisions.
In the K-562 leukemic background, disrupting DRAM2 may abrogate p53-dependent autophagy and apoptosis, potentially contributing to survival advantage and resistance to tyrosine kinase inhibitors like imatinib. This knockout model therefore enables precise dissection of how DRAM2 loss influences BCR-ABL?Cdriven signaling, allowing researchers to assess changes in autophagic markers, lysosomal integrity, and apoptotic sensitivity under genotoxic or therapeutic stress. It provides a physiologically relevant context for evaluating the tumor-suppressive functions of DRAM2 in a hematopoietic malignancy setting.
Typical research applications include investigating autophagy mechanisms, apoptosis signaling, and drug resistance in cancer biology. Researchers can employ Western blotting to monitor DRAM2, LC3-II, and p62 levels; RT-qPCR for transcriptional profiling; flow cytometry with autophagy/lysosome dyes or Annexin V to quantify autophagic flux and apoptosis; confocal microscopy to visualize lysosomal morphology; and BCR-ABL activity assays combined with imatinib sensitivity testing. For detailed technical specifications or custom inquiries, please contact Ascent Research.
